Results 231 to 240 of about 484,668 (274)

Clinical implications of PD‐L1 expression in oncogene‐driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors

open access: yesInternational Journal of Cancer, EarlyView.
What's New? PD‐L1 is a reliable biomarker for predicting immunotherapy efficacy in patients with non‐small‐cell lung cancer lacking oncogenic driver mutations. However, its significance in patients with driver mutations remains unclear. In this study of 273 patients with stage IV non–‐small‐cell lung cancer harboring diverse driver alterations and PD ...
Xiaoxiao Fan   +7 more
wiley   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang   +5 more
wiley   +1 more source

Impact of non‐genetic heterogeneity of BRAF‐mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Patient‐derived organoids (PDOs) model tumor biology and drug response while preserving key tumor features, yet the impact of non‐genetic culture variables is poorly understood. This study examined the influence of organoid size, seeding density, and morphology on growth, drug sensitivity, and Wnt signaling in a colorectal cancer organoid ...
Viktoria Zieger   +6 more
wiley   +1 more source

Globo‐H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Colorectal cancer (CRC) is increasingly complicated by drug‐resistant tumors that limit the effectiveness of anticancer therapies. Because resistance mechanisms vary among patients and can evolve over time, personalized treatment strategies are needed.
Keren Zohar   +16 more
wiley   +1 more source

Unconventional mechanisms of resveratrol in atherosclerosis prevention and management. [PDF]

open access: yesWorld J Exp Med
Chaarani N   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy